Zura Bio Limited Class A

XNAS

Last traded price · USD

$3.87

−3.70%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $4.02
Volume: 112
Day's high: —
Day's low: —

In brief

Zura Bio Limited is a US-listed company listed on Nasdaq, valued at about $373M.
Its shares closed at $4.02 on 4 Nov 2026, up 16.5% over the past year.
From India you can buy ZURA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Zura Bio Limited (ZURA) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ZURA share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ZURA options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY over 1 year
1 month: +1.5% (SPY −1.6%). 3 months: −28.7% (SPY −0.4%). 1 year: +16.5% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ZURA, SPY · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $4.02 was 11.3% below its 50-day average ($4.53) and 23.0% below its 200-day average ($5.22). It has closed below the 200-day for 39 sessions, since 11 Sep 2026. The 50-day average crossed below the 200-day on 2 Oct 2026, 23 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Light volume: 0.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 1.9M shares was 0.5× the average of the 30 sessions before it (4.2M), as the price rose 0.8%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
18% of the way up its 52-week range
Closed at $4.02 on 4 Nov 2026: 46.0% below the 52-week high of $7.44 (10 Mar 2026) and 23.7% above the low of $3.25 (5 Jun 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 7.3% of shares outstanding
7.0M shares were sold short at the 15 Oct 2026 settlement, 7.3% of the 96.3M shares outstanding; covering them would take 1.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.5%

6 months−17.8%

1 year+16.5%

5 years—

Newswire

About

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Website

Notable moves

September 30, 2025
+44.82%
July 17, 2025
+51.94%
March 22, 2023
+314.36%

Newswire

About

Website

Notable moves

September 30, 2025
+44.82%
July 17, 2025
+51.94%
March 22, 2023
+314.36%

Zura Bio Limited Class A

XNAS

Last traded price · USD

$3.87

−3.70%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $4.02
Volume: 112
Day's high: —
Day's low: —

In brief

Zura Bio Limited is a US-listed company listed on Nasdaq, valued at about $373M.
Its shares closed at $4.02 on 4 Nov 2026, up 16.5% over the past year.
From India you can buy ZURA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Zura Bio Limited (ZURA) shares from India?

Do I need the price of a whole ZURA share to invest?

How much can I invest in US stocks in a year?

Can I trade ZURA options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY over 1 year
1 month: +1.5% (SPY −1.6%). 3 months: −28.7% (SPY −0.4%). 1 year: +16.5% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ZURA, SPY · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $4.02 was 11.3% below its 50-day average ($4.53) and 23.0% below its 200-day average ($5.22). It has closed below the 200-day for 39 sessions, since 11 Sep 2026. The 50-day average crossed below the 200-day on 2 Oct 2026, 23 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Light volume: 0.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 1.9M shares was 0.5× the average of the 30 sessions before it (4.2M), as the price rose 0.8%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
18% of the way up its 52-week range
Closed at $4.02 on 4 Nov 2026: 46.0% below the 52-week high of $7.44 (10 Mar 2026) and 23.7% above the low of $3.25 (5 Jun 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 7.3% of shares outstanding
7.0M shares were sold short at the 15 Oct 2026 settlement, 7.3% of the 96.3M shares outstanding; covering them would take 1.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.5%

6 months−17.8%

1 year+16.5%

5 years—

Newswire

About

Website

Notable moves

September 30, 2025
+44.82%
July 17, 2025
+51.94%
March 22, 2023
+314.36%

Newswire

About

Website

Notable moves

September 30, 2025
+44.82%
July 17, 2025
+51.94%
March 22, 2023
+314.36%

Zura Bio Limited Class A

Zura Bio Limited in brief

Ahead of SPY over 1 year

Below its 50- and 200-day averages

Light volume: 0.5× its 30-session average on 4 Nov 2026

18% of the way up its 52-week range

Short interest at 7.3% of shares outstanding

Zura Bio Limited Class A

Zura Bio Limited in brief

Ahead of SPY over 1 year

Below its 50- and 200-day averages

Light volume: 0.5× its 30-session average on 4 Nov 2026

18% of the way up its 52-week range

Short interest at 7.3% of shares outstanding